Karyopharm endometrial cancer trial misses primary endpoint

Karyopharm endometrial cancer trial misses primary endpoint

Karyopharm endometrial cancer trial misses primary endpoint
So far, the selloff hasn’t done much to dent the S&P 500, as other stocks and sectors have picked up the slack
en English Economics Jul 17, 2026 Koffi Alle Building on the success of his mega-refinery in Lagos, Nigerian industrialist Aliko Dangote is in talks to construct a second one in collaboration with several East African countries. African leaders should learn from Dangote’s…
Cloudflare (NET +2.71%) could become a key toll road for the internet as AI agents drive more traffic across the web. Pay Per Crawl gives the company a fascinating new revenue angle, but valuation, competition, and insider selling make the stock a much harder call. *Stock prices used were the market prices of June 27,…
Every company needs working capital, particularly to get things going. Space Exploration Technologies (SPCX 4.51%) is no exception. The timing and scope of SpaceX’s most recent fundraising, however, are a bit of a red flag. We’re not talking about SpaceX’s mid-June initial public offering, which raised proceeds of $85.7 billion when demand exceeded the $75 billion…
The secular decline in birth rates across the globe over the past seven decades has slowed population growth, raised average ages, and reshaped labor markets and the macroeconomy. Contrary to the widespread expectation that these trends hamper economic growth, we find lower birth rates are associated with higher growth in GDP per working-age adult across…
Strategists conclude the IPO wave doesn’t necessarily portend a dangerous market bubble – yet